News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
FDA
Swiss Approve Novartis International AG Drug For Blindness
August 29, 2006
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
ZURICH (Reuters) - Drugmaker Novartis AG said on Tuesday that Switzerland had become the first European country to approve the company's Lucentis drug as a treatment for a leading cause of blindness in people over age 50.
Twitter
LinkedIn
Facebook
Email
Print
FDA
Approvals
Europe
MORE ON THIS TOPIC
Approvals
AstraZeneca, Daiichi Sankyo Move Enhertu to First-Line Metastatic Breast Cancer
December 16, 2025
·
2 min read
·
Tristan Manalac
FDA
J&J Wins Proactive FDA National Priority Voucher for Multiple Myeloma Combo
December 16, 2025
·
2 min read
·
Tristan Manalac
Manufacturing
Big Pharma Pushes FDA To Decouple Inspections From Drug Approval Applications
December 16, 2025
·
4 min read
·
Nick Paul Taylor
Approvals
Milestone’s Long Regulatory Road Ends in Approval for Cardamyst
December 15, 2025
·
2 min read
·
Tristan Manalac
